Navigation Links
Shire Appoints Sylvie Gregoire President of Human Genetic Therapies Business

Seasoned leader brings added expertise to Shire management team

CAMBRIDGE, Mass., and BASINGSTOKE, England, Sept. 24 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, Nasdaq: SHPGY, TSX: SHQ), the global specialty biopharmaceutical company, announced today that Sylvie Gregoire has been appointed President of its Human Genetic Therapies (HGT) business, effective immediately. Sylvie brings more than 20 years of management, regulatory affairs, manufacturing and supply chain experience from biotechnology and pharmaceutical companies including Biogen Idec and Merck & Co. Sylvie replaces David Pendergast, former President of HGT, whose retirement was announced in March of this year. To ensure a smooth transition, David will continue with Shire through 2007 as an advisor.

In her role as President of Shire Human Genetic Therapies and a member of Shire's Management Committee, Sylvie is responsible for setting the strategic direction of the HGT business including managing the commercial and pipeline growth, directing the R&D and portfolio management processes, overseeing the supply teams, and also contributing to the execution of the overall strategic direction of Shire. She will report to Shire Chief Executive Officer, Matthew Emmens, and will be based at the Shire HGT headquarters in Cambridge, MA.

"Sylvie brings an impressive level of knowledge and expertise to Shire HGT, and her leadership will be key to the continued growth of our HGT business as well as to the global organization," said Matthew Emmens, Chief Executive Officer of Shire Pharmaceuticals. "We thank David Pendergast for his contribution towards the transformation of Shire HGT into a highly successful business and for creating an engine of future growth for Shire. We wish him an enjoyable and productive retirement."

Shire HGT has several projects in various stages of development, and over the past 18 months has received approval and launched ELAPRASE(TM) for the treatment of Hunter syndrome in the U.S., Europe, and Canada, among other regions. In addition, REPLAGAL(TM), for the treatment of Fabry disease, which is available in Europe and other regions outside of the US, continues to perform well.

"Shire HGT is well-positioned for sustained growth, with a strong portfolio and pipeline offering a range of potential therapies for patients suffering from genetic diseases," said Sylvie Gregoire, President of Shire HGT. "Elaprase has been successfully launched globally, Replagal continues to perform well and we have some exciting opportunities in our early pipeline as well as in our business development prospects. I am very excited about this new opportunity and look forward to working with a team of professionals dedicated to addressing the needs of patients with genetic diseases, and leading our business through its next phase of development."

Sylvie most recently served as Chairwoman of the Board for IDM Pharma. Prior to IDM Pharma, she was President & Chief Executive Officer of GlycoFi(TM), Inc. (acquired by Merck & Co. in May 2006), a biotechnology company developing biologics independently and with partners. Prior to this, Sylvie was EVP of Technical Operations and a member of the management team at Biogen. She also held various senior clinical and regulatory affairs roles at Merck & Co. in the US and abroad. In addition to serving on the Board of Directors for IDM Pharma, Thallion Pharmaceuticals and Cubist Pharmaceuticals, she was recently appointed to the Board of Directors of the Greater Boston Food Bank. She is also on the Board of Trustees at the International School of Boston. Sylvie received her Doctor of Pharmacy degree from the State University of New York at Buffalo and her pharmacy graduate degree from the Universite Laval in Quebec City, Canada.

Notes to editors


Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT), gastrointestinal (GI) and renal diseases. The structure is sufficiently flexible to allow Shire to target new therapeutic areas to the extent opportunities arise through acquisitions. Shire's in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe. Shire believes that a carefully selected portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.

For further information on Shire, please visit the Company's website:


Statements included herein that are not historical facts are forward-looking statements. Such forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, Shire's results could be materially affected. The risks and uncertainties include, but are not limited to, risks associated with: the inherent uncertainty of pharmaceutical research, product development, manufacturing and commercialization; the impact of competitive products, including, but not limited to the impact of those on Shire's Attention Deficit and Hyperactivity Disorder ("ADHD") franchise; patents, including but not limited to, legal challenges relating to Shire's ADHD franchise; government regulation and approval, including but not limited to the expected product approval date of INTUNIV(TM) (guanfacine) extended release (ADHD); Shire's ability to secure new products for commercialization and/or development; Shire's ability to benefit from its acquisition of New River Pharmaceuticals Inc.; the successful development of JUVISTA(R) (human TGFBeta3) and other risks and uncertainties detailed from time to time in Shire plc's filings with the Securities and Exchange Commission, particularly Shire plc's Annual Report on Form 10-K for the year ended December 31, 2006.

SOURCE Shire plc
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Sharon Ethanol appoints operations director
2. Kyron appoints former AMA chairman to board
3. Brady appoints GE efficiency expert as CTO
4. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
5. Johnson Controls appoints Roell to head EOC
6. SecurePipe appoints two senior execs
7. Milwaukees PointOne appoints new president and CEO
8. Third Wave appoints new chairman
9. Midwest Venture Summit disappoints; Cato grades Midwest governors
10. Sonic Foundry appoints Engineering Dean and Cometa CEO to Board of Directors
11. TeraMEDICA Appoints Prekop as New President
Post Your Comments:
(Date:11/30/2015)... ... November 30, 2015 , ... ... integration with MarkLogic, the Enterprise NoSQL database platform provider, creating a seamless ... , Smartlogic’s Content Intelligence capabilities provide a robust set of semantic tools ...
(Date:11/30/2015)... and PETACH TIKVAH, Israel , Nov. ... BCLI ), a leading developer of adult stem cell ... Brainstorm Cell Therapeutics Ltd., has been awarded an additional grant ... of the Chief Scientist (OCS). This grant, the second this ... 2015 activities to approximately $1.8 million (approximately NIS7 million).  ...
(Date:11/28/2015)... ... November 28, 2015 , ... • Jeon Jin Bio Corp, a ... rodent control solutions , Bird Free, an ... across all sensory modalities including visual, smell, taste and touch, enabling safe, effective avian ...
(Date:11/27/2015)... 27, 2015 /PRNewswire/--  Mallinckrodt plc (NYSE: MNK ... it has closed the sale of its global contrast ... NYSE Euronext) in a transaction valued at approximately $270 ... and a total of approximately 1,000 employees spread across ... St. Louis area. This entire workforce and ...
Breaking Biology Technology:
(Date:11/26/2015)... 26, 2015 Research and Markets ( ... Fingerprint Sensors - Technology and Patent Infringement Risk Analysis" ... --> --> Fingerprint sensors using capacitive ... The fingerprint sensor vendor Idex forecasts an increase of ... mobile devices and of the fingerprint sensor market between ...
(Date:11/20/2015)... 2015 NXTD ) ("NXT-ID" or ... growing mobile commerce market and creator of the Wocket® ... was recently interviewed on The RedChip Money Report ... weekend on Bloomberg Europe , Bloomberg Asia, Bloomberg ... NXTD ) ("NXT-ID" or the "Company"), a biometric ...
(Date:11/19/2015)... Nov. 19, 2015  Based on its in-depth analysis ... recognizes BIO-key with the 2015 Global Frost & Sullivan ... & Sullivan presents this award to the company that ... the needs of the market it serves. The award ... and expands on customer base demands, the overall impact ...
Breaking Biology News(10 mins):